Sugi Predict
/ Targets
/ LMTK2
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to LMTK2 by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Compare the Impact of Xuezhikang and Atorvastatin on Glucose Metabolism in Dyslipidemia Patients With Prediabetes |
PHASE4 | COMPLETED |
| The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus |
PHASE3 | UNKNOWN |
| Evaluating Efficacy of Tivozanib (AV-951) in Biliary Tract Cancers |
PHASE1/PHASE2 | RECRUITING |
| Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria |
PHASE2 | COMPLETED |
| Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors |
PHASE2 | RECRUITING |
| XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer |
PHASE2 | RECRUITING |
| Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy |
PHASE2 | COMPLETED |
| A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... |
PHASE2 | COMPLETED |
| Everolimus for Children With Recurrent or Progressive Ependymoma |
PHASE2 | COMPLETED |
| Selective Treatment According to Molecular Subtype of Prostate Cancer |
PHASE2 | UNKNOWN |
| Study in Adult Ph-positive ALL |
PHASE2 | UNKNOWN |
| Effects of Lithium Therapy on Blood-based Therapeutic Targets in Parkinson's Disease. |
PHASE1 | COMPLETED |
| Nilotinib in Huntington's Disease |
PHASE1 | UNKNOWN |
| Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors |
PHASE1 | COMPLETED |
| Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma |
PHASE1 | COMPLETED |
| A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors |
PHASE1 | UNKNOWN |
| Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 |
EARLY_PHASE1 | COMPLETED |
| Rostock International Parkinson's Disease Study (ROPAD) |
nan | COMPLETED |
| Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies |
nan | RECRUITING |
| Identification of Novel Targetable Kinases in SR-a GvHD |
nan | COMPLETED |
| Clinical Genetics Branch Eligibility Screening Survey |
nan | NOT_YET_RECRUITING |
| NTRK 1,2,3 Rearrangements in Patients With Solid Tumors |
nan | ACTIVE_NOT_RECRUITING |
| Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA |
nan | RECRUITING |
| A Retrospective Clinical Records Review of Patients Diagnosed With Gastrointestinal Stromal Tumour at Two Tertiary Institutes in Singapore |
nan | COMPLETED |
| Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus |
nan | COMPLETED |
| LRRK2 Activity and Markers of Parkinson's Disease in G2385R Carriers |
nan | COMPLETED |
| Prospective Monocentric Clinical-biological Database |
nan | RECRUITING |
| Molecular Phenotype Changes and Personalized Treatment for CRPC |
nan | UNKNOWN |
| Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients |
nan | COMPLETED |
| Immune Cell Response to Stimuli |
nan | RECRUITING |
Related proteins — ESM-2 sequence neighbours (a LMTK2 binder may also engage these)